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Abstract
Background: Data on outpatient care provided to patients at high cardiovascular risk in Brazil are insufficient.
Objective: To describe the profile and document the clinical practice of outpatient care in patients at high cardiovascular 
risk in Brazil, regarding the prescription of evidence-based therapies.
Methods: Prospective registry that documented the ambulatory clinical practice in individuals at high cardiovascular risk, 
which was defined as the presence of the following factors: coronary artery disease, cerebrovascular and peripheral vascular 
diseases, diabetes, or those with at least three of the following factors: hypertension, smoking, dyslipidemia, age > 70 years, 
family history of coronary artery disease, chronic kidney disease or asymptomatic carotid artery disease. Basal characteristics 
were assessed and the rate of prescription of pharmacological and non-pharmacological interventions was analyzed.
Results: A total of 2364 consecutive patients were included, of which 52.2% were males, with a mean age of 66.0 years 
(± 10.1). Of these, 78.3% used antiplatelet agents, 77.0% used statins and of patients with a history of myocardial infarction, 
58.0% received beta-blockers. Concomitant use of these three classes of drugs was 34%; 50.9% of hypertensive, 67% of 
diabetic and 25.7% of dyslipidemic patients did not achieve the goals recommended by guidelines. The main predictors of 
prescription therapies with proven benefit were centers with a cardiologist and history of coronary artery disease.
Conclusion: This national and representative registry identified important gaps in the incorporation of therapies with 
proven benefit, offering a realistic outlook of patients at high cardiovascular risk (Arq Bras Cardiol. 2013;100(3):212-220).
Keywords: Cardiovascular Diseases / mortality; Review, Cross-Sectional Studies; Risk Factors; Drug Prescriptions; 
Randomized Controlled Trials as Topic.
Introduction
The projection of the Global Burden of Diseases study1 
for 2020 indicates that cardiovascular diseases remain 
the leading cause of death and disability, particularly in 
developing countries. In Brazil, the incidence has been 
increasing over the years and, in parallel, the expenses 
devoted to treatment have been progressively increasing, 
both in the setting of public assistance, as well as private 
health care2-4.
Several large randomized trials and systematic reviews 
have shown that in patients with high cardiovascular risk, 
the benefit of drugs such as statins extends even to patients 
with normal cholesterol levels5; antiplatelets are capable of 
reducing major cardiovascular events, even in individuals 
with no clinical manifestations of atherosclerosis6 and many 
antihypertensive drugs, mainly angiotensin-converting 
enzyme inhibitors (ACEI), have the potential to reduce 
cardiovascular events, even in patients with no diagnostic 
criteria for systemic arterial hypertension7. Additionally, non-
pharmacological interventions, such as cardioprotective diets, 
smoking cessation and regular physical activity, although the 
data are less robust than those in studies with pharmacological 
therapies, are also associated with a reduction in clinically 
relevant outcomes8-22.
In view of the importance of using evidence-based 
therapies for cardiovascular risk reduction, it is essential to 
assess daily clinical practice. International registries have 
shown significant gaps in the incorporation of guideline 
recommendations into the real world. To date, no registry 
has fully documented Brazilian clinical practice in relation DOI: 10.5935/abc.20130062
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to the care of individuals at high cardiovascular risk in 
a large and representative sample, which contemplated 
both public and private centers from all regions of Brazil. 
Thus, the objective of this study was to document the 
current clinical practice through patterns of prescription 
of evidence-based interventions in patients at high 
cardiovascular risk in Brazil.
Methods
The complete methodology of REACT has been previously 
published23. Briefly, this is a cross-sectional observational 
and prospective registry with longitudinal follow-up of 
patients, with blinded assessment of outcomes. This project 
was conceived and coordinated by the Brazilian Cardiology 
Society (SBC), with the participation of public and private 
centers from all regions of Brazil, respecting the distribution 
of population according to data from the Brazilian Institute 
of Geography and Statistics (Instituto Brasileiro de Geografia 
e Estatística - IBGE). Public and private centers, university 
and non-university ones, were invited to participate in the 
study, from both large cities and small towns, which met the 
minimum requirements of Good Clinical Research Practice.
Study population (eligibility criteria)
We included consecutive individuals of both genders, aged 
45 years and older that met at least one of the criteria for 
high cardiovascular risk classification: coronary artery disease 
(CAD), cerebrovascular disease (CVD), peripheral vascular 
disease and diabetes mellitus. It also included patients with 
at least three risk factors for atherosclerosis: hypertension, 
smoking, dyslipidemia, age > 70 years, family history of CAD, 
chronic kidney disease or asymptomatic carotid artery disease. 
All included patients were outpatients. 
We excluded patients with neurocognitive or psychiatric 
conditions that prevented obtaining reliable clinical data 
(defined by the investigators’ clinical decisions), as well as 
patients with tumors of unfavorable clinical course.
Outcomes of interest
The primary outcome referring to this analysis was the 
proportion of patients using evidence-based therapies 
(defined as concurrent use of antiplatelet agents, statins 
and ACE inhibitors) during the baseline consultation of 
the REACT study, considering a minimum prescription 
rate of 90%.
Other outcomes included: the proportion of patients 
who received recommendations regarding measures of 
lifestyle changes (smoking cessation, physical activity 
and nutrition guidelines) and proportion of patients who 
received each of the following medications individually 
during the baseline consultation: statins, antiplatelet 
agents, ACE inhibitors, beta-blockers (analysis restricted to 
patients with a history of myocardial infarction) and thiazide 
diuretics (in hypertensive patients).
Additionally, we calculated the rate of hypertensive 
and dyslipidemic patients with controlled levels within the 
recommended therapeutic goals, as recommended by SBC. 
Data quality control
The participating centers were trained regarding the 
study procedures and electronic systems, either in person 
or by phone, by the coordination team. Data quality control 
was performed through different strategies, such as use of 
electronic data capture system, central statistical monitoring 
of collected variables, sporadic sending of reports containing 
the status of patients at participating centers and direct check 
of 10% of the records in five centers with higher recruitment. 
Additionally 20% of the medical records from 20% of the 
remaining centers were checked after being chosen randomly 
within each national demographic region.
Finally, biannual meetings were held in order to update 
their status and discuss, among participating researchers, 
relevant points of the registry.
Sample size calculation
In order to detect a proportion of 40% for the occurrence 
of the primary outcome, considering a sampling error of 2%, 
a two-sided alpha of 5% and a statistical power of 90% were 
required, thus resulting in the inclusion of at least 2,305 patients.
Statistical analysis
Quantitative variables were expressed as mean and 
standard deviation, whereas qualitative variables were 
expressed as absolute and relative frequencies. The primary 
and secondary outcomes were described by estimates 
weighted by the number of patients at each center, which 
ranged from 3 to 213. The assessment of the association 
between concomitant use of antiplatelet agents, statins 
and ACE inhibitors and factors such as gender, age, region, 
specialty and type of center was performed using a multiple 
logistic regression model. The results of model adjustment 
were shown as odds ratios (OR) and 95% confidence 
intervals (95%CI). All analyses were performed with the 
statistical software Statistical Package for Social Science 
(SPSS), release 16.0 (SPSS Inc., Chicago, IL, USA) and R 2.13 
(R Development Core Team, 2011, http://www.R-project.
org/.), considering two-tailed significance level of 5%. 
Ethical and good clinical practice aspects
The protocol was approved by the Research Ethics Committee 
(REC) of Hospital do Coração de São Paulo, in São Paulo (SP), 
on June 22, 2010 under registration number 118/2010 and 
subsequently, each participating center also had its local approval. 
All patients signed a free and informed consent form, and the 
trial was carried out according to the principles of the current 
review of the Declaration of Helsinki and Good Clinical Practice 
Guidelines, in its latest version, as well as Edict 196/96.
Results
A total of 2,403 patients were enrolled at 45 centers 
between July 2010 and December 2011 and this analysis 
included only patients with complete baseline data, totaling 
2,364 patients. Of this sample, 60.3% were from the 
Southeast, 26.1% from the South, 9.3% from the Northeast, 
2.7% from the North and 1.6% from the Midwest.
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Figure 1 - Assistance care profile. Analysis considering a total of 2,364 patients.
31.0%
28,6%.
40.5% mixed
public
supplemental
The care profile of these patients showed a predominance 
of mixed institutions (40.5%), followed by Supplemental 
Health Institutions (31%) and, finally, 28.6% that belonged 
to the Brazilian Unified Health System (SUS), as shown 
in Figure 1. Most patients were recruited from centers 
specialized in cardiology (84.6%); patients were also 
recruited from primary care centers (6.8%), endocrinology 
(2.3%), nephrology (2.3%) and internal medicine 
(2.3%) departments.
Sociodemographic characteristics
Table 1 shows the sample sociodemographic characteristics. 
In this sense, of the 2,364 patients studied, mean age was 
66.0 ± 10.1 years, 55.2% were males, 68.4% self-reported 
as being Caucasian, 7.8% were illiterate and 73.9% had a 
body mass index (BMI) ≥ 25. Among the cardiovascular risk 
factors, the most prevalent was hypertension (92.1%), followed 
by dyslipidemia (75.3%). 
Prescription of lifestyle change measures
Figure 2 shows the frequency of recommendations 
regarding changes in lifestyle. Of the patients included, 
83% received formal recommendations about diet, 77.5% 
on the benefits of physical activity and 77.1% on the risks 
of smoking.
Evidence-based drug-therapy prescription
Of the 2,364 patients analyzed, 78.3% received antiplatelet 
agents, 77.0% statins and 53.0% ACE inhibitors. Among the 
681 patients with a history of myocardial infarction, 79.4% 
received beta-blockers (Figure 3).
The combined use of antiplatelet agents, statins and ACE 
inhibitors was observed in 34% of patients, with a higher frequency 
of use (40.1%) in 1,249 patients with CAD, when compared to 
other categories of high cardiovascular risk (Figure 4).
Cardiovascular risk factor control according to 
guideline-established goals
Regarding the attainment of goals determined by SBC 
guidelines, we observed that in 51.2% of 1,328 diabetic 
patients, blood glucose levels were higher than the 
recommended ones. In relation to hypertension control, 
50.9% of 2,180 patients were hypertensive, with blood 
pressure levels higher than a usual blood pressure of 
140/90 mmHg. Finally, regarding lipid goals recommended 
for patients at high cardiovascular risk, about 20% to 30% 
of the sample had LDL levels ≥ 100 mg/dL (Figure 5).
Predictors of evidence-based pharmacological therapy 
prescription
A multivariate logistic regression was performed to assess 
independent factors associated with increased likelihood of 
prescription of evidence-based therapies (defined for this 
analysis as the combined use of aspirin, statins and ACE 
inhibitors). Accordingly, among the independent predictors, 
we highlight the service performed by a cardiologist 
(OR = 1.42, 95% CI: 1.10 - 1.82) and CAD diagnosis 
(OR = 1.91, 95% CI: = 1.59 - 2.30) (Figure 6).
Discussion
Main findings
The REACT study represents the largest and most recent 
national registry, coordinated by a medical society and 
involving patients at high cardiovascular risk treated in an 
outpatient setting, from all regions of the country. The main 
finding of this study refers to the fact that risk factor control 
(according to guideline goals for LDL, blood pressure and 
blood glucose levels) is lower than the expected and that 
there are opportunities for improvement in clinical practice, 
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Table 1 - Basal characteristics 
Basal characteristics All (n = 2.364)n (%)
Age (years) 66.0 ± 10.1
Male gender 1.234 (52.2) 
Ethnicity 
White 1.616 (68.4)
Black 294 (12.4)
Mulatto 424 (17.9)
Body mass index
≥ 25 1.747 (73.9)
Eligibility criteria 
CAD 1.248 (52.2)
Previous acute myocardial infarction 681 (28.8)
Cerebrovascular accident 295 (12.5)
Diabetes 1.327 (56.1)
Peripheral disease 268 (11.3)
Multiple risk factors 1.342 (56.8)
Hypertension 2.178 (92.1)
Dyslipidemia 1.781 (75.3)
Diabetic nephropathy 167 (7.0)
Age > 70 years 856 (36.2)
Smoking 236 (10.0)
Family history of CAD 975 (41.2)
Asymptomatic carotid disease 229 (9.7)
BP
Systolic 132.3 ± 21.2
Diastolic 78.9 ± 12.4
Laboratory assessment 
Total cholesterol (mg/dL) 176.6 ± 46.6
LDL (mg/dL) 100.5 ± 49.7
HDL (mg/dL) 47.3 ± 24.8
Triglycerides (mg/dL) 158.7 ± 118.9
Glycemia (mg/dL) 124.5 ± 50.9
Glycated hemoglobin (%) 7.1 ± 3.5
Creatinine (mg/dL) 1.1 ± 0.7
CAD: coronary artery disease; BP: blood pressure.
especially concerning the prescription of evidence-based 
interventions and mainly the combined use of statins, 
antiplatelets and ACEI. Among the factors independently 
associated with the prescription of evidence-based therapies, 
we highlight treatment by cardiologists and CAD diagnosis.
Comparison with previous literature
The findings of this study showed that patients at high 
cardiovascular risk treated at Brazilian centers of excellence 
have a demographic pattern and are receive treatment similar to 
those seen in recent registries carried out in North America and 
Western Europe. In this sense, the most prevalent risk factors in 
the Brazilian population were hypertension and dyslipidemia, 
which is consistent with literature. The multicenter REACH 
study, for instance, reported a prevalence of hypertension and 
dyslipidemia of 81.3% and 70.4%, respectively, similar to that 
found in this registry, as well as in similar publications24.
The adequate control of diabetes mellitus in the REACT 
study was unsatisfactory, as only 23% of diabetics maintained 
levels of glycated hemoglobin < 7%, even though these 
patients have greater cardiovascular risk than non-diabetic 
ones25. The IV Brazilian Guidelines on Dyslipidemia and 
Atherosclerosis Prevention of the Brazilian Society of 
Cardiology26 recommends, for high-risk individuals, the 
simultaneous start of nonpharmacological measures and 
treatment with lipid-lowering drugs. The REACT study showed 
that 88% of patients were instructed on cardioprotective diets 
and 77% were taking lipid-lowering drugs; however, a minority 
of dyslipidemic patients undergoing secondary prevention, 
diabetics, patients with CAD, CVD, or PAD reached levels 
<100 mg/dL of LDL cholesterol. The L-TAP 2 study, which 
assessed between 2006 and 2007 approximately 10,000 
patients from nine countries with dyslipidemia who used statins, 
found that 73% had achieved their goals of LDL cholesterol, 
as defined by national guidelines, with greater control found 
among low-risk patients (86%), when compared to those at 
high risk (67%)26.
Recent international and national studies have shown a gap 
between guidelines and clinical practice, particularly for those 
patients at higher risk for the development of cardiovascular 
events. Data from the PREMISE study27, carried out by the 
World Health Organization (WHO) in 2005, which included 
10,000 patients in developing countries (one thousand patients 
from Brazil) showed that only about 30% of patients with 
high cardiovascular risk who had indication for drug therapy 
were taking statins and ACE inhibitors and only 80% received 
antiplatelet agents. These findings are consistent with those from 
the REACT study, considering that antiplatelet agents, statins 
and ACE inhibitor prescription rates were 78.3%, 72.6% and 
53.0%, respectively. The REACT adds additional information to 
the findings of the PREMISE study27 as the latter, in Brazil, was 
carried out exclusively in the South region. Other observational 
studies have also demonstrated findings consistent with those 
from the REACT study in relation to the prescription of evidence-
based therapies in the real world. Thus, in the REACH study24 
of 31,195 patients assessed, 72.6% were using statins, 43.3% 
used ACEI and 69% used antiplatelets. As it included a larger 
number of Brazilian centers, including non-university centers 
and centers located in small towns, the REACT study added 
additional important information regarding the findings of the 
REACH study. In communities located in developing countries, 
the gaps are even more significant. The PURE study, which 
included 153,662 patients from 18 countries (both developed 
and developing ones), aged between 35 and 75 years, living in 
urban and rural areas, between January 2003 and December 
2009, found even more disturbing numbers. Among the 
population with CAD, only 25.8% used antiplatelets and 16.7% 
used statins. When we evaluated only the developed countries, 
these rates increased to 64.1% and 70.9%, respectively28.
215
Special Article
Berwanger et al.
REACT Registry Baseline data
Arq Bras Cardiol. 2013;100(3):212-220
Figure 3 – Evidence-based drug use. ACEI: angiotensin-converting enzyme inhibitors; AMI: acute myocardial infarction.
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100%
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Figure 2 - Nonpharmacological measures. Analysis considering a total of 2,364 patients.
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Figure 4 - Use of evidence-based drugs (antiplatelet agents, statins and angiotensin-converting enzyme inhibitors), according to the clinical history. Analysis considering 
a total of 2,364 patients. CAD: coronary artery disease; CVA/TIA: cerebrovascular accident / transient ischemic attack; DM: diabetes mellitus; PAD: peripheral arterial 
disease.
100%
80%
60%
40%
20%
0%
40.1%
35.6% 35.1% 31.7%
CAD CVA/TIA DM PAD
Figure 5 - Control of risk factors according to the goals determined by the guidelines. DM: diabetes mellitus; PAD: peripheral arterial disease, CVA/TIA: cerebrovascular 
accident / transient ischemic attack, CAD: coronary artery disease; pts: patients.
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LDL ≥ 100 mg/dL (pts with PAD)
LDL ≥ 100 mg/dL (pts with CVA/TIA)
LDL ≥ 100 mg/dL (pts with CAD)
Blood pressure ≥ 140/90 mmHg (Hypertensive pts)
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Among the factors independently associated with 
prescription of evidence-based therapies, treatment by 
cardiologists and diagnosis of CAD are highlighted. The 
findings of the present study are consistent with recent 
cross-sectional study carried out in ten European countries 
that analyzed quality indicators in 8928 patients, showing 
that risk factor control was better in the group with known 
coronary artery disease, when compared to those with 
high risk and no cardiovascular disease, for both rates of 
uncontrolled blood pressure (34.2 vs. 49.3%, p < 0.001) 
and uncontrolled cholesterol (32.4 versus 64.5%, p < 0.001), 
which may reproduce drug prescription29.
Strength and limitations
The main strengths of the REACT study are the fact that 
it represents the largest and most recent national registry 
that documents care of patients at high cardiovascular risk, 
its supra-institutional characteristic (as it was carried out by 
SBC), the participation of centers from all Brazilian regions, 
including public (university and non-university), private and 
mixed hospitals, both from capital and large cities, as well as 
from smaller towns. The latter aspect represents a differential 
of the REACT study in relation to international registries with 
the participation of Brazilian centers, which are usually carried 
out in large university centers only, which have academic 
tradition. Additionally, robust methodology was used regarding 
the observational study design of the registry type, namely: 
minimization of selection bias by including a consecutive 
sample of patients, adequate control of random error through 
satisfactory sample size and robust statistical methods, 
minimizing measurement bias by central adjudication of 
outcomes, and finally, the use of several strategies validated for 
data quality control and fraud prevention system (electronic 
capture of data, central statistical consistency checking, as well 
as local and at-distance monitoring centers).
On the other hand there are limitations that must be 
mentioned. It is noteworthy that, although it included 
primary care center units and other specialty centers, most 
centers included were specialized in Cardiology. Thus, 
potentially, the inclusion of a greater number of patients 
from Basic Health Units and communities with less access to 
specialized services could disclose an even greater gap in the 
incorporation of evidence-based therapies and satisfactory 
control of risk factors, according to guideline targets. However, 
Figure 6 - Factors associated with adherence to evidence-based drugs. Analysis considering a total of 2,364 patients. CAD: coronary artery disease, ASA: acetylsalicylic 
Acid; ACEI: angiotensin-converting enzyme inhibitors.
CAD
Center specialized in 
Cardiology
Public
Mixed
Type of center 
(supplemental)
South or southeast
Age (years)
Male sex
Characteristic
Favors concomitant adherence to
ASA/ACEI/Statins
3.0
Does not favor
2.01.00.0
OR
1.91
1.42
1.99
1.96
1.00
1.14
0.99
1.15
(1.59 ; 2.30)
(1.10 ; 1.82)
(1.54 ; 2.59)
(1.51 ; 2.53)
(1.00 ; 1.00)
(0.86 ; 1.52)
(0.98 ; 0.99)
(0.97 ; 1.37)
95% CI
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from a qualitative point of view (i.e., presence of gaps in the 
incorporation of evidence), the results would remain similar, 
even with the inclusion of those centers.
Additionally, although we have tried to respect the 
geographical distribution of the population according to the 
last census of the Brazilian Institute of Geography and Statistics 
(IBGE), the number of centers in the North, Northeast and 
Midwest was lower than the representativeness of centers 
in the South and Southeast regions. Finally, this analysis 
shows baseline data only, with no description of longitudinal 
follow-up of patients that might allow measurement of the 
incidence and predictors of cardiovascular events. Regarding 
this latter point, it is important to mention that new analyses 
of the REACT study, regarding the longitudinal follow-up, are 
in progress and will probably bring relevant information on the 
incidence of clinically relevant outcomes in this population. 
Conclusion and main implications
The goals of cardiovascular risk factor control, drug 
prescriptions and recommendations for lifestyle change for 
patients at high cardiovascular risk in Brazil, were outside 
of those recommended by the Brazilian guidelines. Given 
the abovementioned facts and based on the results of the 
REACT study, it is necessary to develop Clinical Practice 
Improvement Programs under the coordination of the 
SBC, including research (cluster randomized trials) and 
professional training, also involving non-specialists.
Although the analysis did not include only patients 
eligible for pharmacologic intervention, considering that the 
rate of contraindication to antiplatelet therapy, statins and 
ACE inhibitors is below 5%, an optimal rate of prescription 
would be around 95%. Thus, the REACT results showed 
that the prescription of cardiovascular drugs is lower than 
the expected.
Finally, it is necessary to carry out similar studies in patients 
in the community with less access to specialists’ services, 
where larger gaps are expected regarding the incorporation 
of therapies with proven benefit. 
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